Preclinical studies have demonstrated that FcγR binding by anti-programmed cell death protein 1 antibodies can induce antibody–dependent phagocytosis of T-cells by tumor-associated macrophages, thereby potentially counteracting the intended T-cell-mediated antitumor immunity. This evidence concerns the gene PDCD1 and neoplasm.